skip to main content
Language:
Search Limited to: Search Limited to: Resource type Show Results with: Show Results with: Search type Index

Results 1 - 20 of 34  for All Library Resources

Sorted by: Sorted by: RelevanceOr hit Enter to replace sort method
Results 1 2 next page
Refined by: Database: PubMed (Medline) remove Database: Taylor & Francis Open Access remove language: Japanese remove
Result Number Material Type Add to My Shelf Action Record Details and Options
1
Stress-induced cardiomyopathy (Takotsubo)--broken heart and mind?
Stress-induced cardiomyopathy (Takotsubo)--broken heart and mind?
Material Type:
Article 		Add to My Research

Stress-induced cardiomyopathy (Takotsubo)--broken heart and mind?

Vascular health and risk management, 2013-01, Vol.9 (default), p.149-154 [Peer Reviewed Journal]

COPYRIGHT 2013 Dove Medical Press Limited ;COPYRIGHT 2013 Dove Medical Press Limited ;2013. This work is licensed under https://creativecommons.org/licenses/by-nc/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2013 Redfors et al, publisher and licensee Dove Medical Press Ltd 2013 ;ISSN: 1178-2048 ;ISSN: 1176-6344 ;EISSN: 1178-2048 ;DOI: 10.2147/vhrm.s40163 ;PMID: 23626469

Full text available

Citations Cited by
2
Diabetic cardiomyopathy: from the pathophysiology of the cardiac myocytes to current diagnosis and management strategies
Diabetic cardiomyopathy: from the pathophysiology of the cardiac myocytes to current diagnosis and management strategies
Material Type:
Article 		Add to My Research

Diabetic cardiomyopathy: from the pathophysiology of the cardiac myocytes to current diagnosis and management strategies

Vascular health and risk management, 2010-01, Vol.6 (default), p.883-903 [Peer Reviewed Journal]

2010. This work is licensed under https://creativecommons.org/licenses/by-nc/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2010 Voulgari et al, publisher and licensee Dove Medical Press Ltd. ;ISSN: 1178-2048 ;ISSN: 1176-6344 ;EISSN: 1178-2048 ;DOI: 10.2147/vhrm.s11681 ;PMID: 21057575

Full text available

Citations Cited by
3
Sitagliptin attenuates cardiomyopathy by modulating the JAK/STAT signaling pathway in experimental diabetic rats
Sitagliptin attenuates cardiomyopathy by modulating the JAK/STAT signaling pathway in experimental diabetic rats
Material Type:
Article 		Add to My Research

Sitagliptin attenuates cardiomyopathy by modulating the JAK/STAT signaling pathway in experimental diabetic rats

Drug design, development and therapy, 2016-01, Vol.10, p.2095-2107 [Peer Reviewed Journal]

COPYRIGHT 2016 Dove Medical Press Limited ;COPYRIGHT 2016 Dove Medical Press Limited ;2016. This work is licensed under https://creativecommons.org/licenses/by-nc/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2016 Al-Rasheed et al. This work is published and licensed by Dove Medical Press Limited 2016 ;ISSN: 1177-8881 ;EISSN: 1177-8881 ;DOI: 10.2147/dddt.s109287 ;PMID: 27418808

Full text available

Citations Cited by
4
SGLT2 Inhibitors: A Novel Player in the Treatment and Prevention of Diabetic Cardiomyopathy
SGLT2 Inhibitors: A Novel Player in the Treatment and Prevention of Diabetic Cardiomyopathy
Material Type:
Article 		Add to My Research

SGLT2 Inhibitors: A Novel Player in the Treatment and Prevention of Diabetic Cardiomyopathy

Drug design, development and therapy, 2020-01, Vol.14, p.4775-4788 [Peer Reviewed Journal]

COPYRIGHT 2020 Dove Medical Press Limited ;COPYRIGHT 2020 Dove Medical Press Limited ;2020. This work is licensed under https://creativecommons.org/licenses/by-nc/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2020 Li and Zhou. 2020 Li and Zhou. ;ISSN: 1177-8881 ;EISSN: 1177-8881 ;DOI: 10.2147/DDDT.S269514 ;PMID: 33192053

Full text available

Citations Cited by
5
Diffuse, marked, reversible impairment in coronary microcirculation in stress cardiomyopathy: A Doppler transthoracic echo study
Diffuse, marked, reversible impairment in coronary microcirculation in stress cardiomyopathy: A Doppler transthoracic echo study
Material Type:
Article 		Add to My Research

Diffuse, marked, reversible impairment in coronary microcirculation in stress cardiomyopathy: A Doppler transthoracic echo study

Annals of medicine (Helsinki), 2009, Vol.41 (6), p.462-470 [Peer Reviewed Journal]

2009 Informa UK Ltd All rights reserved: reproduction in whole or part not permitted 2009 ;2009 INIST-CNRS ;ISSN: 0785-3890 ;EISSN: 1365-2060 ;DOI: 10.1080/07853890903022793 ;PMID: 19492201

Digital Resources/Online E-Resources

Citations Cited by
6
Clinical aspects of Emery-Dreifuss muscular dystrophy
Clinical aspects of Emery-Dreifuss muscular dystrophy
Material Type:
Article 		Add to My Research

Clinical aspects of Emery-Dreifuss muscular dystrophy

Nucleus (Austin, Tex.), 2018-01, Vol.9 (1), p.314-320 [Peer Reviewed Journal]

2018 The Author. Published by Informa UK Limited, trading as Taylor & Francis Group 2018 ;2018 The Author. Published by Informa UK Limited, trading as Taylor & Francis Group 2018 The Author ;ISSN: 1949-1034 ;EISSN: 1949-1042 ;DOI: 10.1080/19491034.2018.1462635 ;PMID: 29633897

Full text available

Citations Cited by
7
Two founder mutations in the alpha-tropomyosin and the cardiac myosin-binding protein C genes are common causes of hypertrophic cardiomyopathy in the Finnish population
Two founder mutations in the alpha-tropomyosin and the cardiac myosin-binding protein C genes are common causes of hypertrophic cardiomyopathy in the Finnish population
Material Type:
Article 		Add to My Research

Two founder mutations in the alpha-tropomyosin and the cardiac myosin-binding protein C genes are common causes of hypertrophic cardiomyopathy in the Finnish population

Annals of medicine (Helsinki), 2013-02, Vol.45 (1), p.85-90 [Peer Reviewed Journal]

2013 Informa UK, Ltd. 2013 ;ISSN: 0785-3890 ;EISSN: 1365-2060 ;DOI: 10.3109/07853890.2012.671534 ;PMID: 22462493

Digital Resources/Online E-Resources

Citations Cited by
8
T1 Mapping and Extracellular Volume in Cardiomyopathy Showing Left Ventricular Hypertrophy: Differentiation Between Hypertrophic Cardiomyopathy and Hypertensive Heart Disease
T1 Mapping and Extracellular Volume in Cardiomyopathy Showing Left Ventricular Hypertrophy: Differentiation Between Hypertrophic Cardiomyopathy and Hypertensive Heart Disease
Material Type:
Article 		Add to My Research

T1 Mapping and Extracellular Volume in Cardiomyopathy Showing Left Ventricular Hypertrophy: Differentiation Between Hypertrophic Cardiomyopathy and Hypertensive Heart Disease

International journal of general medicine, 2022-01, Vol.15, p.4163-4173 [Peer Reviewed Journal]

2022 Liang et al. ;2022 Liang et al. 2022 Liang et al. ;ISSN: 1178-7074 ;EISSN: 1178-7074 ;DOI: 10.2147/ijgm.s350673 ;PMID: 35465304

Full text available

Citations Cited by
9
Inotersen: new promise for the treatment of hereditary transthyretin amyloidosis
Inotersen: new promise for the treatment of hereditary transthyretin amyloidosis
Material Type:
Article 		Add to My Research

Inotersen: new promise for the treatment of hereditary transthyretin amyloidosis

Drug design, development and therapy, 2019-05, Vol.13, p.1515-1525 [Peer Reviewed Journal]

COPYRIGHT 2019 Dove Medical Press Limited ;COPYRIGHT 2019 Dove Medical Press Limited ;2019. This work is licensed under https://creativecommons.org/licenses/by-nc/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2019 Mathew and Wang. This work is published and licensed by Dove Medical Press Limited 2019 ;ISSN: 1177-8881 ;EISSN: 1177-8881 ;DOI: 10.2147/dddt.s162913 ;PMID: 31118583

Full text available

Citations Cited by
10
Natural compounds as inhibitors of transthyretin amyloidosis and neuroprotective agents: analysis of structural data for future drug design
Natural compounds as inhibitors of transthyretin amyloidosis and neuroprotective agents: analysis of structural data for future drug design
Material Type:
Article 		Add to My Research

Natural compounds as inhibitors of transthyretin amyloidosis and neuroprotective agents: analysis of structural data for future drug design

Journal of enzyme inhibition and medicinal chemistry, 2020-01, Vol.35 (1), p.1145-1162 [Peer Reviewed Journal]

2020 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. 2020 ;2020 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. This work is licensed under the Creative Commons Attribution License http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2020 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. 2020 The Author(s) ;ISSN: 1475-6366 ;EISSN: 1475-6374 ;DOI: 10.1080/14756366.2020.1760262 ;PMID: 32419519

Full text available

Citations Cited by
11
Spotlight on aldoxorubicin (INNO-206) and its potential in the treatment of soft tissue sarcomas: evidence to date
Spotlight on aldoxorubicin (INNO-206) and its potential in the treatment of soft tissue sarcomas: evidence to date
Material Type:
Article 		Add to My Research

Spotlight on aldoxorubicin (INNO-206) and its potential in the treatment of soft tissue sarcomas: evidence to date

OncoTargets and therapy, 2019-01, Vol.12, p.2047-2062 [Peer Reviewed Journal]

COPYRIGHT 2019 Dove Medical Press Limited ;2019. This work is licensed under https://creativecommons.org/licenses/by-nc/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2019 Cranmer. This work is published and licensed by Dove Medical Press Limited 2019 ;ISSN: 1178-6930 ;EISSN: 1178-6930 ;DOI: 10.2147/ott.s145539 ;PMID: 30936721

Full text available

Citations Cited by
12
Updated clinical overview on cardiac laminopathies: an electrical and mechanical disease
Updated clinical overview on cardiac laminopathies: an electrical and mechanical disease
Material Type:
Article 		Add to My Research

Updated clinical overview on cardiac laminopathies: an electrical and mechanical disease

Nucleus (Austin, Tex.), 2018-01, Vol.9 (1), p.380-391 [Peer Reviewed Journal]

2018 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. 2018 ;2018 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. 2018 The Author(s) ;ISSN: 1949-1034 ;EISSN: 1949-1042 ;DOI: 10.1080/19491034.2018.1489195 ;PMID: 29929425

Full text available

Citations Cited by
13
In-hospital and long-term mortality in Takotsubo cardiomyopathy: a community hospital experience
In-hospital and long-term mortality in Takotsubo cardiomyopathy: a community hospital experience
Material Type:
Article 		Add to My Research

In-hospital and long-term mortality in Takotsubo cardiomyopathy: a community hospital experience

Journal of community hospital internal medicine perspectives, 2016, Vol.6 (3), p.31082-9 [Peer Reviewed Journal]

2016 Olga Vriz et al. 2016 ;Copyright Taylor & Francis Ltd. 2016 ;ISSN: 2000-9666 ;EISSN: 2000-9666 ;DOI: 10.3402/jchimp.v6.31082 ;PMID: 27406446

Full text available

Citations Cited by
14
Molecular remodeling of ion channels, exchangers and pumps in atrial and ventricular myocytes in ischemic cardiomyopathy
Molecular remodeling of ion channels, exchangers and pumps in atrial and ventricular myocytes in ischemic cardiomyopathy
Material Type:
Article 		Add to My Research

Molecular remodeling of ion channels, exchangers and pumps in atrial and ventricular myocytes in ischemic cardiomyopathy

Channels (Austin, Tex.), 2010-03, Vol.4 (2), p.101-107 [Peer Reviewed Journal]

Copyright © 2010 Landes Bioscience 2010 ;ISSN: 1933-6950 ;EISSN: 1933-6969 ;DOI: 10.4161/chan.4.2.10975 ;PMID: 20090424

Full text available

Citations Cited by
15
Edaravone inhibits pressure overload-induced cardiac fibrosis and dysfunction by reducing expression of angiotensin II AT1 receptor
Edaravone inhibits pressure overload-induced cardiac fibrosis and dysfunction by reducing expression of angiotensin II AT1 receptor
Material Type:
Article 		Add to My Research

Edaravone inhibits pressure overload-induced cardiac fibrosis and dysfunction by reducing expression of angiotensin II AT1 receptor

Drug design, development and therapy, 2017-01, Vol.11, p.3019-3033 [Peer Reviewed Journal]

2017. This work is licensed under https://creativecommons.org/licenses/by-nc/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2017 Zhang et al. This work is published and licensed by Dove Medical Press Limited 2017 ;ISSN: 1177-8881 ;EISSN: 1177-8881 ;DOI: 10.2147/dddt.s144807 ;PMID: 29081650

Full text available

Citations Cited by
16
Alpha-Mangostin Improves Cardiac Hypertrophy and Fibrosis and Associated Biochemical Parameters in High-Fat/High-Glucose Diet and Low-Dose Streptozotocin Injection-Induced Type 2 Diabetic Rats
Alpha-Mangostin Improves Cardiac Hypertrophy and Fibrosis and Associated Biochemical Parameters in High-Fat/High-Glucose Diet and Low-Dose Streptozotocin Injection-Induced Type 2 Diabetic Rats
Material Type:
Article 		Add to My Research

Alpha-Mangostin Improves Cardiac Hypertrophy and Fibrosis and Associated Biochemical Parameters in High-Fat/High-Glucose Diet and Low-Dose Streptozotocin Injection-Induced Type 2 Diabetic Rats

Journal of experimental pharmacology, 2020, Vol.12, p.27-38 [Peer Reviewed Journal]

2020 Soetikno et al. ;COPYRIGHT 2020 Dove Medical Press Limited ;COPYRIGHT 2020 Dove Medical Press Limited ;2020. This work is licensed under https://creativecommons.org/licenses/by-nc/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2020 Soetikno et al. 2020 Soetikno et al. ;ISSN: 1179-1454 ;EISSN: 1179-1454 ;DOI: 10.2147/jep.s233111 ;PMID: 32095085

Full text available

Citations Cited by
17
An Overview of Investigational and Experimental Drug Treatment Strategies for Marfan Syndrome
An Overview of Investigational and Experimental Drug Treatment Strategies for Marfan Syndrome
Material Type:
Article 		Add to My Research

An Overview of Investigational and Experimental Drug Treatment Strategies for Marfan Syndrome

Journal of experimental pharmacology, 2021-08, Vol.13, p.755-779 [Peer Reviewed Journal]

COPYRIGHT 2021 Dove Medical Press Limited ;2021. This work is licensed under https://creativecommons.org/licenses/by-nc/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2021 Deleeuw et al. 2021 Deleeuw et al. ;ISSN: 1179-1454 ;EISSN: 1179-1454 ;DOI: 10.2147/JEP.S265271 ;PMID: 34408505

Full text available

Citations Cited by
18
Hutchinson–Gilford Progeria Syndrome: Clinical and Molecular Characterization
Hutchinson–Gilford Progeria Syndrome: Clinical and Molecular Characterization
Material Type:
Article 		Add to My Research

Hutchinson–Gilford Progeria Syndrome: Clinical and Molecular Characterization

Application of clinical genetics, 2020-09, Vol.13, p.159-164 [Peer Reviewed Journal]

2020. This work is licensed under https://creativecommons.org/licenses/by-nc/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2020 Pachajoa et al. 2020 Pachajoa et al. ;ISSN: 1178-704X ;EISSN: 1178-704X ;DOI: 10.2147/TACG.S238715 ;PMID: 32943904

Full text available

Citations Cited by
19
99mTc-DPD uptake reflects amyloid fibril composition in hereditary transthyretin amyloidosis
99mTc-DPD uptake reflects amyloid fibril composition in hereditary transthyretin amyloidosis
Material Type:
Article 		Add to My Research

99mTc-DPD uptake reflects amyloid fibril composition in hereditary transthyretin amyloidosis

Upsala journal of medical sciences, 2016-01, Vol.121 (1), p.17-24 [Peer Reviewed Journal]

2016 Taylor & Francis 2016 ;2016 Taylor & Francis. This work is licensed under the Creative Commons Attribution License http://creativecommons.org/Licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;ISSN: 0300-9734 ;EISSN: 2000-1967 ;DOI: 10.3109/03009734.2015.1122687 ;PMID: 26849806

Full text available

Citations Cited by
20
Profile of sacubitril/valsartan in the treatment of heart failure: patient selection and perspectives
Profile of sacubitril/valsartan in the treatment of heart failure: patient selection and perspectives
Material Type:
Article 		Add to My Research

Profile of sacubitril/valsartan in the treatment of heart failure: patient selection and perspectives

Vascular health and risk management, 2017-01, Vol.13, p.369-382 [Peer Reviewed Journal]

COPYRIGHT 2017 Dove Medical Press Limited ;COPYRIGHT 2017 Dove Medical Press Limited ;2017. This work is licensed under https://creativecommons.org/licenses/by-nc/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2017 Yandrapalli et al. This work is published and licensed by Dove Medical Press Limited 2017 ;ISSN: 1178-2048 ;ISSN: 1176-6344 ;EISSN: 1178-2048 ;DOI: 10.2147/vhrm.s114784 ;PMID: 29042791

Full text available

Citations Cited by

Results 1 - 20 of 34  for All Library Resources

Sorted by: Sorted by: RelevanceOr hit Enter to replace sort method
Results 1 2 next page

Personalize your results

  1. Edit

Refine Search Results

Expand My Results

  1.   
INSPIRE LIBRARY - TON DUC THANG UNIVERSITY (84-028) 37 755 057 Feedback
19 Nguyen Huu Tho St. Dist.7, HCM thuvien@tdtu.edu.vn

Copyright © 2017 INSPIRE LIBRARY - TON DUC THANG UNIVERSITY

Searching Remote Databases, Please Wait